12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study

Riccardo De Giorgi(Warneford Hospital), Maxime Taquet(Oxford Health NHS Foundation Trust), Philip J. Cowen(University of Oxford), Ivan Koychev(John Radcliffe Hospital), Amanda Adler(Oxford Centre for Diabetes, Endocrinology and Metabolism), Paul J. Harrison(King's College London), Catherine J. Harmer(Warneford Hospital)

EClinicalMedicine

July 10, 2024

10.1016/j.eclinm.2024.102726

Cited by 59

Related Papers

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

|The Lancet Psychiatry|2021|2.2k

Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA

|The Lancet Psychiatry|2020|1.5k

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

|The Lancet|2021|997

Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

|PLoS Medicine|2021|983

Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients

|The Lancet Psychiatry|2022|722